Quick Answer
KYNTRA BIO, INC. reported Net Income Loss of $183.45 million for the year ending 2025.
- KYNTRA BIO, INC. showed an increase of +485.6% in Net Income Loss from 2024 to 2025.
- This data is from KYNTRA BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), KYNTRA BIO, INC.'s Net Income Loss has grown by 1,327.7%.
- Historical annual values: Fiscal year 2025: $183.45 million | Fiscal year 2024: -$47.58 million | Fiscal year 2023: -$284.23 million | Fiscal year 2022: -$293.65 million | Fiscal year 2021: -$290.02 million | Fiscal year 2020: -$189.29 million | Fiscal year 2019: -$76.97 million | Fiscal year 2018: -$86.42 million | Fiscal year 2017: -$120.88 million | Fiscal year 2016: -$58.07 million | Fiscal year 2015: -$85.78 million | Fiscal year 2014: -$59.50 million | Fiscal year 2013: -$14.94 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: